Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis
Zhi-Hao Zhang, Feng Wei, Nosratola D Vaziri, Xian-Long Cheng, Xu Bai, Rui-Chao Lin, Ying-Yong Zhao, Zhi-Hao Zhang, Feng Wei, Nosratola D Vaziri, Xian-Long Cheng, Xu Bai, Rui-Chao Lin, Ying-Yong Zhao
Abstract
Chronic kidney disease (CKD) is a major public health problem worldwide. Rhubarb has been shown to have nephroprotective and anti-fibrotic activities in patients with CKD. However, bioactive fractions and biochemical mechanism of anti-fibrotic properties of rhubarb remain unclear. Here we applied ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry together with univariate and multivariate statistical analyses to investigate the urinary metabolite profile in rats with adenine-induced CKD treated with the petroleum ether (PE)-, ethyl acetate (EA)- and n-butanol (BU)- extracts of rhubarb. Significant differences in renal function, kidney histopathology as well as metabolic profiles were observed between CKD and control rats. Changes in these parameters reflected characteristic phenotypes of CKD rats. We further identified a series of differential urinary metabolites for CKD rats, suggesting metabolic dysfunction in pathway of amino acid, purine, taurine, and choline metabolisms. Treatment with EA, BU and PE extracts of rhubarb improved renal function and histopathological abnormalities including interstitial fibrosis and inflammation, and either fully or partially reversed the abnormalities of the urinary metabolites. Among them, the nephroprotective effect of EA extract was stronger than BU and PE extracts. This work provides important mechanistic insights into the CKD and nephroprotective effects of different rhubarb extract against tubulo-interstitial fibrosis.
Figures
References
- Lameire N., Jager K., Van Biesen W., de Bacquer D. & Vanholder R. Chronic kidney disease: a European perspective. Kidney Int. 68, S30–38 (2005).
- Levey A. S. et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 72, 247–59 (2007).
- Zeisberg M. & Neilson E. G. Mechanisms of tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 21, 1819–34 (2010).
- Agarwal S. K., Singh S. S., Lakshmi V., Verma S. & Kumar S. Chemistry and pharmacology of rhubarb (Rheum species)—a review. J. Sci. Ind. Res. 60, 1–9 (2001).
- Kashiwada Y., Nonaka G. I. & Nishioka I. Studies on Rhubarb (Rhei Rhizoma). XV: Simultaneous determination of phenolic constituents by high-performance liquid chromatography. Cheml. Pharm. Bull. 37, 999–1004 (1989).
- Wang J. et al. Assessment of the renal protection and hepatotoxicity of rhubarb extract in rats. J. Ethnopharmacol. 124, 18–25 (2009).
- Mitsuma T., Yokozawa T., Oura H. & Terasawa K. [Rhubarb therapy in patients with chronic renal failure (Part 2)]. Nihon Jinzo Gakkai Shi 29, 195–207 (1987).
- Li X. & Wang H. Chinese herbal medicine in the treatment of chronic kidney disease. Adv. Chronic Kidney Dis. 12, 276–81 (2005).
- Yokozawa T., Suzuki N., Zheng P. D., Oura H. & Nishioka I. Effect of orally administered rhubarb extract in rats with chronic renal failure. Chem. Pharm. Bull. 32, 4506–13 (1984).
- Zhao Y. Y. & Lint R. C. Metabolomics in nephrotoxicity. Adv. Clin. Chem. 65, 69–89 (2014).
- Zhang A. et al. Metabolomics: towards understanding traditional Chinese medicine. Planta Med. 76, 2026–35 (2010).
- Zhao Y. Y. Metabolomics in chronic kidney disease. Clin. Chim. Acta 422, 59–69 (2013).
- Zhao Y. Y. & Lin R. C. UPLC-MSE application in disease biomarker discovery: the discoveries in proteomics to metabolomics. Chem. Biol. Interact. 215, 7–16 (2014).
- Zhao Y. Y., Cheng X. L., Vaziri N. D., Liu S. & Lin R. C. UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin. Biochem. 47, 16–26 (2014).
- Zhao Y. Y., Cheng X. L., Wei F., Bai X. & Lin R. C. Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high-sensitivity mass spectrometry with MSE data collection technique. Biomarkers 17, 721–729 (2012).
- Zhao Y. Y. et al. Serum metabonomics study of adenine-induced chronic renal failure rat by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers 17, 48–55 (2012).
- Zhao Y. Y., Liu J., Cheng X. L., Bai X. & Lin R. C. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin. Chim. Acta 413, 642–649 (2012).
- Zhao Y. Y. et al. UPLC-Q-TOF/HSMS/MSE-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4,6,8(14),22-tetraen-3-one. Chem. Biol. Interact. 301, 31–38 (2013).
- Zhao Y. Y., Li H. T., Feng Y. L., Bai X. & Lin R. C. Urinary metabonomic study of the surface layer of Poria cocos as an effective treatment for chronic renal injury in rats. J. Ethnopharmacol. 148, 403–10 (2013).
- Yokozawa T. et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 44, 230–4 (1986).
- Peterson J. W., Boldogh I., Popov V. L., Saini S. S. & Chopra A. K. Anti-inflammatory and antisecretory potential of histidine in Salmonella-challenged mouse small intestine. Lab. Invest. 78, 523–34 (1998).
- Watanabe M. et al. Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. Am. J. Clin. Nutr. 87, 1860–6 (2008).
- Stockenhuber F., Aunder-Plassmann G. & Baleke P. Increased plasma histamine levels in chronic renal failure. N. Engl. J. Med. 317, 386 (1987).
- Gill D. S. et al. Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J. Clin. Pathol. 44, 243–5 (1991).
- Choi J. Y. et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol. Dial. Transplant 26, 1304–1313 (2011).
- Posada-Ayala M. et al. Identification of a urine metabolomic signature in patients with advanced-stage chronic kidney disease. Kidney Int. 85, 103–11 (2014).
- Lameire N., Vanholder R. & De Smet R. Uremic toxins and peritoneal dialysis. Kidney Int. 59, S292–297 (2001).
- Wong J. et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 39, 230–7 (2014).
- Wikoff W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. 106, 3698–703 (2009).
- La S., Yoo H. H. & Kim D. H. Liquid chromatography-mass spectrometric analysis of urinary metabolites and their pattern recognition for the prediction of drug-induced hepatotoxicity. Chem. Res. Toxicol. 18, 1887–96 (2005).
- Vaziri N. D. et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83, 308–15 (2013).
- Pawlak K., Kowalewska A., Mysliwiec M. & Pawlak D. Kynurenine and its metabolites–kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion molecules and oxidative status in patients with chronic kidney disease. Am. J. Med. Sci. 338, 293–300 (2009).
- Zhao J. Plasma kynurenic acid/tryptophan ratio: a sensitive and reliable biomarker for the assessment of renal function. Ren. Fail 35, 648–53 (2013).
- Mutsaers H. A. et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One 6, e18438 (2011).
- Byrd D. J. et al. Indolic tryptophan metabolism in uraemia. Proc. Eur. Dial. Transplant Assoc. 12, 347–54 (1976).
- Garibotto G. et al. Causes of hyperhomocysteinemia in patients with chronic kidney diseases. Semin. Nephrol. 26, 3–7 (2006).
- McGregor D. O. et al. Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 59, 2267–72 (2001).
- Skiba W. E., Taylor M. P., Wells M. S., Mangum J. H. & Awad W. M. Jr. Human hepatic methionine biosynthesis. Purification and characterization of betaine:homocysteine S-methyltransferase. J. Biol. Chem. 257, 14944–8 (1982).
- Wyngaarden J. B. & Dunn J. T. 8-Hydroxyadenine as the intermediate in the oxidation of adenine to 2, 8-dihydroxyadenine by xanthine oxidase. Arch. Biochem. Biophys. 70, 150–6 (1957).
- de Vries A. & Sperling O. Implications of disorders of purine metabolism for the kidney and the urinary tract. Ciba. Found. Symp. 48, 179–206 (1977).
- Ayvazian J. H. & Skupp S. The Study of Purine Utilization and Excretion in a Xanthinuric Man. J. Clin. Invest. 44, 1248–60 (1965).
- Yamamoto T., Moriwaki Y. & Takahashi S. Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). Clin. Chim. Acta 356, 35–57 (2005).
- Shahbazian H., Zand Moghadam A., Ehsanpour A. & Khazaali M. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis. Iran. J. Kidney Dis. 3, 151–5 (2009).
- Spencer H. W., Yarger W. E. & Robinson R. R. Alterations of renal function during dietary-induced hyperuricemia in the rat. Kidney Int. 9, 489–500 (1976).
- Jalal D. I., Chonchol M., Chen W. & Targher G. Uric acid as a target of therapy in CKD. Am. J. Kidney Dis. 61, 134–46 (2013).
- Sanchez-Lozada L. G. et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron. Physiol. 108, 69–78 (2008).
- Kosugi T. et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am. J. Physiol. Renal Physiol. 297, 481–8 (2009).
- Suliman M. E., Barany P., Filho J. C., Lindholm B. & Bergstrom J. Accumulation of taurine in patients with renal failure. Nephrol. Dial. Transplant 17, 528–9 (2002).
- Bergstrom J., Alvestrand A., Furst P. & Lindholm B. Sulphur amino acids in plasma and muscle in patients with chronic renal failure: evidence for taurine depletion. J. Intern. Med. 226, 189–94 (1989).
- Fontana M., Pecci L., Dupre S. & Cavallini D. Antioxidant properties of sulfinates: protective effect of hypotaurine on peroxynitrite-dependent damage. Neurochem. Res. 29, 111–6 (2004).
- Hayashi K. et al. Use of serum and urine metabolome analysis for the detection of metabolic changes in patients with stage 1-2 chronic kidney disease. Nephro. Urol. Mon. 3, 164–171 (2011).
- Bain M. A., Faull R., Fornasini G., Milne R. W. & Evans A. M. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol. Dial. Transplant 21, 1300–4 (2006).
- Hauet T. et al. Influence of retrieval conditions on renal medulla injury: evaluation by proton NMR spectroscopy in an isolated perfused pig kidney model. J. Surg. Res. 93, 1–8 (2000).
- Hauet T., Gibelin H., Godart C., Eugene M. & Carretier M. Kidney retrieval conditions influence damage to renal medulla: evaluation by proton nuclear magnetic resonance (NMR) pectroscopy. Clin. Chem. Lab. Med. 38, 1085–92 (2000).
- Wang Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
- Zhao Y. Y. et al. A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/HDMS. Plos One 9, e115467 (2014).
- Zhao Y. Y. et al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-beta1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MSE. J. Proteome. Res. 12, 692–703 (2013).
- Zhao Y. Y. et al. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. PLoS One 8, e59617 (2013).
- Vaziri N. D. et al. High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease. PLoS One 9, e114881 (2014).
- Junqueira L. C., Bignolas G. & Brentani R. R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 11, 447–55 (1979).
- Li L. et al. Total extract of Yupingfeng attenuates bleomycin-induced pulmonary fibrosis in rats. Phytomedicine 22, 111–9 (2015).
- Jansson J. et al. Metabolomics reveals metabolic biomarkers of Crohn’s disease. PLoS One 4, e6386 (2009).
- Benjamini Y. & Hochberg Y. controlling the false discovery rate-a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).
- Storey J. D. A direct approach to false discovery rates. J. R. Stat. Soc. B 2002, 479–498 (2002).
Source: PubMed